The company received approval for two changes in NaropinÒ labelling: the first allows for dose increase from 5.0 mg/mL to 7.5 mg/mL for Major Nerve Blocks; the second grants approval for an increase in the duration of Naropin infusion from 24 hours to 72 hours for post-operative pain management.

Naropin® is the only long acting anaesthetic with a 72-hour infusion indication.

Other anaesthetic products developed and manufactured by AstraZeneca include Diprivan® Injectable Emulsion, EMLA® , EMLA® Anaesthetic Disc Topical Adhesive System and Xylocaine®.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with healthcare sales of over $15 billion and leading positions in sales of gastrointestinal, oncology, anaesthesia including pain management, cardiovascular, central nervous system (CNS) and respiratory products.